About Michael Poisel
Michael Poisel is a director at Linnaeus Therapeutics.
Michael Poisel first appears on SEC filings in 2018.
Experience
This experience comes from Michael Poisel's profile and from SEC filings. For roles taken from filings, the years are when the filings name Michael Poisel in the role, so the role may have started earlier or lasted longer.
CC
CEO Investor Connection Current
Partner
2026 – Present
MC
Melbourne Entrepreneurial Centre Current
Executive Director, Melbourne Entrepreneurial Centre
2025 – Present
Linnaeus Therapeutics, Inc. Current
Director
2016 – Present · Haddonfield, NJ
Develops experimental medicines for people with cancer.
ET
Exyn Technologies
Board Director
2014 – 2026
ES
Ed Leadership Sims
Board Director
2013 – 2025
UP
University of Pennsylvania
Executive Director, PCI Ventures
2009 – 2025
PH
PhylloPharma
Chief Executive Officer
2022 – 2023
US
U.S. Department of State
YTILI Reverse Fellow
2022
GP
Greater Philadelphia Alliance for Capital & Technologies (PACT)
Board Member
2017 – 2019
NE
NewSpring
Principal
2002 – 2009
AP
Apax Partners
Partner
1998 – 2001
GE
GE Equity
Venture Capital Associate
1997 – 1998
GA
GE Astrospace
Supervisor
1990 – 1995
Key Colleagues at Startups
The people Michael Poisel works with at each company, as listed on that company's latest Form D.
Linnaeus Therapeutics, Inc. · Form D/A, Apr 2, 2026
JD
James Demetriades
Director
CA
Chris Arendt
Director
TT
Todd Thomson
Director
PM
Patrick Mooney
CEO and director
JL
John Lepping
Director